Biotech Values

[rancherho]

Dr. Petrylak’s 11/06 presentation to the Chemotherapy Foundation on the use of Taxotere (docetaxel) after Provenge is at: http://chemotherapyfoundation.org/professional_education/meetingarchives_tcf2006_main.html

If you do the math with Dr. Small's Halabi data, the increased survival for the roughly 1/3 (51 of 147) patients in integrated 9901 and 9902a ITT database who received the combination Provenge + Taxotere therapy represent about 80% of the increased median survival of the combined P and P+T ITT patients and the Provenge alone patients represent < 2 months of increased survival. It implicitly raises a question whether the treatment effect of Provenge (or any immunotherapy in AIPC) could achieve statistical significance without the assist of docetaxel. The Ph2 GVAX data also supports the importance of docetaxel after GVAX therapy for increased median survival. As Sgt Friday used to say: Just the facts.